Fenimore Christopher R.
SEC CIK 1697422 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | SVP Ctrl | 24.6K | — | $23.97M | 37 | 2021-08-20 | 2026-08-18 |
Most active insiders at REGN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | POON CHRISTINE A | Dir | — | $4.25M |
| 2 | McCourt Marion | EVP Commercial | — | $2.00M |
| 3 | Zoghbi Huda Y | Dir | — | $1.92M |
| 4 | Pitofsky Jason | VP Ctrl | — | $1.87M |
| 5 | Bassler Bonnie L | Dir | — | $1.77M |
| 6 | Guarini Kathryn | Dir | — | $660.0K |
| 7 | RYAN ARTHUR F | Dir | — | $434.7K |
| 8 | MURPHY ANDREW J | EVP Research | — | — |
| 9 | Fenimore Christopher R. | EVP Fin CFO | — | — |
| 10 | Schenkein David P | Dir | — | — |
Transactions 37
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-20 16:01 | 2026-08-18 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | EVP Fin CFO | M - OptEx | $381.92 | +6,283 | 24.6K | +34% | +$2.40M |
| D | 2026-08-20 16:01 | 2026-08-18 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | EVP Fin CFO | F - Tax | $813.47 | -4,599 | 20.0K | -19% | -$3.74M |
| D | 2025-12-09 | 2025-12-08 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | EVP Fin CFO | F - Tax | $712.94 | -992 | 18.3K | -5% | -$707.2K |
| D | 2025-12-09 | 2025-12-05 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | EVP Fin CFO | A - Grant | $0.00 | +3,027 | 19.3K | +19% | $0 |
| 2024-12-18 | 2024-12-16 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | CFO, SVP Fin | F - Tax | $730.81 | -491 | 16.3K | -3% | -$358.8K | |
| D | 2024-12-10 | 2024-12-06 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | CFO, SVP Fin | A - Grant | $0.00 | +2,591 | 17.9K | +17% | $0 |
| D | 2024-12-10 | 2024-12-09 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | CFO, SVP Fin | F - Tax | $787.00 | -1,140 | 16.8K | -6% | -$897.2K |
| MI | 2024-08-29 | 2024-08-28 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | CFO, SVP Fin | S - Sale | $1,205.33 | -5,680 | 450 | -93% | -$6.85M |
| M | 2024-02-12 | 2024-02-09 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | CFO, SVP Fin | S - Sale | $953.31 | -4,919 | 17.4K | -22% | -$4.69M |
| DM | 2024-01-25 | 2024-01-23 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $477.67 | +10.0K | 22.9K | +78% | +$4.78M |
| DM | 2024-01-25 | 2024-01-23 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $948.50 | -7,569 | 17.9K | -30% | -$7.18M |
| DM | 2024-01-04 | 2024-01-03 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $912.30 | -7,512 | 15.3K | -33% | -$6.85M |
| DM | 2024-01-04 | 2024-01-03 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $477.67 | +10.0K | 19.4K | +107% | +$4.78M |
| 2023-12-29 | 2023-12-27 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | S - Sale | $856.71 | -2,448 | 14.4K | -15% | -$2.10M | |
| M | 2023-12-26 | 2023-12-21+ | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | S - Sale | $844.30 | -1,930 | 16.8K | -10% | -$1.63M |
| 2023-12-14 | 2023-12-12 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $856.71 | -2,552 | 18.8K | -12% | -$2.19M | |
| D | 2023-12-12 | 2023-12-08 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | A - Grant | $0.00 | +2,370 | 22.8K | +12% | $0 |
| DM | 2023-12-12 | 2023-12-08+ | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $844.02 | -2,010 | 21.3K | -9% | -$1.70M |
| D | 2023-08-25 | 2023-08-23 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $399.66 | +7,000 | 26.1K | +37% | +$2.80M |
| D | 2023-08-25 | 2023-08-23 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $842.66 | -5,198 | 20.9K | -20% | -$4.38M |
| 2023-03-27 | 2023-03-23 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | S - Sale | $806.47 | -2,192 | 18.4K | -11% | -$1.77M | |
| D | 2023-02-07 | 2023-02-03 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $774.29 | -3,286 | 20.3K | -14% | -$2.54M |
| D | 2023-02-07 | 2023-02-03 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $270.43 | +5,000 | 23.6K | +27% | +$1.35M |
| D | 2022-12-20 | 2022-12-16 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | A - Grant | $0.00 | +1,926 | 18.6K | +12% | $0 |
| MI | 2022-12-13 | 2022-10-26 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | G - Gift | $0.00 | 0 | 461 | New | $0 |
| 2022-12-13 | 2022-12-09 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $753.28 | -247 | 16.7K | -1% | -$186.1K | |
| 2022-10-07 | 2022-10-05 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | S - Sale | $749.00 | -1,844 | 16.4K | -10% | -$1.38M | |
| 2022-10-05 | 2022-10-03 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | S - Sale | $724.00 | -3,346 | 18.3K | -15% | -$2.42M | |
| DM | 2022-04-11 | 2022-04-08 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $736.21 | -5,606 | 25.1K | -18% | -$4.13M |
| DM | 2022-04-11 | 2022-04-08 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $364.23 | +7,450 | 27.2K | +38% | +$2.71M |
| DM | 2022-04-01 | 2022-03-31 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $700.99 | -8,654 | 21.6K | -29% | -$6.07M |
| DM | 2022-04-01 | 2022-03-31 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $317.97 | +12.0K | 31.6K | +61% | +$3.82M |
| 2021-12-14 | 2021-12-11 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $664.34 | -270 | 21.1K | -1% | -$179.4K | |
| D | 2021-12-10 | 2021-12-08 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | A - Grant | $0.00 | +1,859 | 21.4K | +10% | $0 |
| A | 2021-08-25 | 2021-08-20 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | F - Tax | $664.85 | -8,719 | 19.0K | -31% | -$5.80M |
| DM | 2021-08-24 | 2021-08-23 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | S - Sale+OE | $655.31 | -4,781 | 27.8K | -15% | -$3.13M |
| D | 2021-08-24 | 2021-08-20 | REGN | Regeneron Pharmaceuticals | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $179.13 | +13.5K | 32.5K | +71% | +$2.42M |
Purchase Sale Sale after option exercise All abbreviations